Sarepta Therapeutics spike amid news of critic's FDA departure
September 14, 2016 at 10:50 AM EDT
Sarepta Therapeutics surge Wednesday after reports a critic of its muscular dystrophy drug left the U.S. Food and Drug Administration.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.